Clinical Trials
Sep 05, 2026 · 1 min read · 21,750 views
Viking touts once-a-month maintenance data for its weight loss candidate
L
Liam Turner
Editorial · Sep 05, 2026
Viking Therapeutics says patients who switched to a once-a-month dosing regimen of its obesity drug did not regain much weight after 12 weeks, bolstering the potential of a less frequent schedule. The company, which is
← Previous
BridgeBio Oncology slides as it tightens the scope of its KRAS program
Next →
Pacing the Journey: A Framework to Commercial Readiness
